ライフサイエンスコーパス: ertapenem

1 emale) with HS were treated with intravenous ertapenem.

2 before and after treatment with intravenous ertapenem.

3 were changed for ESBL-PE carriers to receive ertapenem.

4 and 271 patients were randomized to receive ertapenem.

5 ronidazole, ciprofloxacin/metronidazole, and ertapenem.

6 enem; 130 of them were skin-tested also with ertapenem.

7 orin-based prophylaxis with 221 who received ertapenem.

8 statistical criteria for the superiority of ertapenem.

9 In this study, the efficacy of ertapenem 1 g once a day was equivalent to piperacillin/

10 We assigned patients intravenous ertapenem (1 g daily; n=295) or piperacillin/tazobactam

11 l antibiotics (n = 288) received intravenous ertapenem (1 g/d) for 2 days followed by oral levofloxac

12 d to antibiotic therapy received intravenous ertapenem (1 g/d) for 3 days followed by 7 days of oral

13 d eravacycline, 1.0 mg/kg every 12 hours, or ertapenem, 1.0 g every 24 hours, for a minimum of four 2

14 < .0001), ciprofloxacin (63.0%, P < .0001), ertapenem (73.4%, P < .0001), tobramycin (80.1%, P < .00

15 eat groups, 245 of 311 patients treated with ertapenem (79.3%) were cured, as were 232 of 304 (76.2)

16 biologically evaluable patients treated with ertapenem (86.7%) were cured, as were 157 of the 193 (81

17 n 77.1%, tobramycin 88.3%, gentamicin 88.8%, ertapenem 91.0%, amikacin 97.5%, and meropenem 98.2%.

18 Ertapenem, a long-acting carbapenem, may be an alternati

19 enyl ring positioned on the C3 side chain of ertapenem acts as an effective internal Raman intensity

20 trometry demonstrated that the doripenem and ertapenem acyl-enzyme complexes remain stable over a tim

21 ealed an isomerization occurring in the BlaC-ertapenem adduct in which the original Delta(2)-pyrrolin

22 lephone survey, treating HS with intravenous ertapenem, administered for a mean of 13 weeks, was asso

23 ing mutations for select carbapenems such as ertapenem also enables higher resistance frequencies and

24 However, its slow rate of the hydrolysis to ertapenem also led to the presence of large amounts of c

25 71 patients were treated with Ertapenem and 71 patients were treated with Ampicillin-S

26 Enterobacteriaceae were also tested against ertapenem and cefotaxime.

27 icant decreases in resistance were noted for ertapenem and cefoxitin.

28 ith the carbapenem antibiotics meropenem and ertapenem and determined the structures of complexes of

29 the Enterobacteriaceae, nonsusceptibility to ertapenem and imipenem predicted the presence of bla(KPC

30 he detection of carbapenemase activity using ertapenem and liquid chromatography-tandem mass spectrom

31 usceptibility results, in vivo studies using ertapenem and meropenem in a rabbit model of P. acnes en

32 Reducing the ertapenem and meropenem ZDs to <=25 mm improved specific

33 Ertapenem and piperacillin-tazobactam were each active a

34 rates were similar for the 226 who received ertapenem and the 219 who received piperacillin/tazobact

35 ined as carbapenem-nonsusceptible (excluding ertapenem) and extended-spectrum cephalosporin-resistant

36 nts discharged with daptomycin, ceftaroline, ertapenem, and novel beta-lactam-beta-lactamase inhibito

37 susceptibility to penicillin, metronidazole, ertapenem, and piperacillin-tazobactam.

38 tibiotics included: daptomycin, ceftaroline, ertapenem, and the novel beta-lactam beta-lactam inhibit

39 cy and safety of antibiotic prophylaxis with ertapenem, as compared with cefotetan, in patients under

40 bound to imipenem, meropenem, doripenem, and ertapenem, as well as the expanded-spectrum cephalospori

41 dose of 600 mg every 8 hours) or intravenous ertapenem (at a dose of 1 g every 24 hours) for 7 to 10

42 Using an ertapenem breakpoint of 0.25 mug/ml would efficiently de

43 orin-deficient Enterobacterales resistant to ertapenem but not other carbapenems; (3) Enterobacterale

44 were susceptible to cefepime, imipenem, and ertapenem but that with a high inoculum, more of these s

45 to be resistant to imipenem, meropenem, and ertapenem by disk diffusion susceptibility testing.

46 Cefazolin and ertapenem combination therapy was used successfully to s

47 how that OXA-24/40 exhibits a preference for ertapenem compared with meropenem, imipenem, and doripen

48 soak was determined to 2.2 A, while the BlaC-ertapenem complex obtained after a 90 min soak was deter

49 Direct ertapenem disk testing is simpler, more sensitive, and m

50 treaking swabs on MAC onto which a 10-microg ertapenem disk was then placed (method 2).

51 eta-lactams imipenem (IPM), meropenem (MEM), ertapenem (ERT), and ceftazidime (CAZ).

52 Imipenem (IPM), meropenem (MEM), ertapenem (ERT), and doripenem (DOR) were tested by brot

53 n of daptomycin (DAP) plus ampicillin (AMP), ertapenem (ERT), or ceftaroline has been demonstrated to

54 184) ST131 bacteremia cohort had detectable ertapenem (ETP) mutational frequencies, with a positive

55 We evaluated detection of ertapenem (ETP) resistance and Klebsiella pneumoniae car

56 s of CRE infections using ceftriaxone (CRO), ertapenem (ETP), and meropenem (MEM) and demonstrate agr

57 in vitro synergy was modest, cefazolin plus ertapenem exhibited synergistic action in a rat model of

58 floxacin compared with 2 days of intravenous ertapenem followed by 5 days of levofloxacin and metroni

59 mbinations of clindamycin and rifampicin, or ertapenem followed by combination rifampicin, moxifloxac

60 openem etzadroxil/probenecid or 5 days of IV ertapenem followed by oral ciprofloxacin or amoxicillin-

61 etzadroxil/probenecid was not noninferior to ertapenem followed by oral step-down therapy for the tre

62 sensitivity and specificity of meropenem and ertapenem for carbapenemase activity among non-Enterobac

63 n group or an active oral drug or parenteral ertapenem for the comparator group after 4 days.

64 eravacycline demonstrated noninferiority to ertapenem for the treatment of patients with cIAI.

65 stridium difficile infection was 1.7% in the ertapenem group and 0.6% in the cefotetan group (P=0.22)

66 ps was surgical-site infection: 17.1% in the ertapenem group and 26.2% in the cefotetan group (absolu

67 ntion-to-treat analysis, and 672 (338 in the ertapenem group and 334 in the cefotetan group) were inc

68 analysis, the failure rate was 28.0% in the ertapenem group and 42.8% in the cefotetan group (absolu

69 ly assigned to study groups, 901 (451 in the ertapenem group and 450 in the cefotetan group) qualifie

70 verall prophylactic failure was 40.2% in the ertapenem group and 50.9% in the cefotetan group (absolu

71 group and 260 of 271 patients [95.9%] in the ertapenem group).

72 In the Ertapenem group, 69 of the 71 patients (97%) were treate

73 270 in the eravacycline group and 271 in the ertapenem group.

74 % in the eravacycline group and 87.6% in the ertapenem group.

75 ears and 55.4 years for the eravacycline and ertapenem groups, respectively.

76 Ertapenem has a pharmacokinetic profile and antimicrobia

77 at C-2 of carbapenem (e.g., benzoic acid of ertapenem) has significant impact on the absorption and

78 nd the carbapenems, meropenem, imipenem, and ertapenem, have been studied by Raman microscopy.

79 nem inactivation method and a MIC screen for ertapenem, imipenem, and meropenem.

80 acy and safety of eravacycline compared with ertapenem in adult hospitalized patients with complicate

81 nd safety of eravacycline in comparison with ertapenem in patients with cIAI requiring surgical or pe

82 il hydrobromide as compared with intravenous ertapenem in patients with complicated urinary tract inf

83 -Sulbactam to that of a three-day regimen of Ertapenem in patients with localized peritonitis ranging

84 hydrobromide was noninferior to intravenous ertapenem in the treatment of complicated urinary tract

85 Ertapenem is more effective than cefotetan in the preven

86 Ertapenem, isoniazid, pyrazinamide, and metronidazole ha

87 established zone diameter (ZD) criteria for ertapenem (<=27 mm) and meropenem (<=32 mm) result in hi

88 The results of this trial suggest that ertapenem may be a useful option that could eliminate th

89 ective intravenous antibiotics, specifically ertapenem, may provide favorable clinical outcomes.

90 opionibacterium acnes ophthalmic isolates to ertapenem, meropenem, and cefepime by utilizing the Etes

91 crog/ml, and 1 microg/ml to 12 microg/ml for ertapenem, meropenem, and cefepime, respectively.

92 The imipenem, meropenem, doripenem, and ertapenem MIC50 values were 4, 2, 1, and 4 mug/ml, respe

93 pyrrolidin-4-ylthio containing side chain of ertapenem (MK-0826) is described.

94 Ertapenem nonsusceptibility had a low positive predictiv

95 H) from 2000 to 2018 for CNSC, as defined by ertapenem nonsusceptibility.

96 From this isolate collection, all ertapenem-nonsusceptible isolates (MIC, >/=1 mug/ml; n =

97 es that harbored a carbapenemase gene (1,485 ertapenem-nonsusceptible isolates and 8 ertapenem-suscep

98 ), and carbapenems (imipenem, meropenem, and ertapenem) obtained utilizing an isosteric deacylation-d

99 f patients with BSI-E initially treated with ertapenem or antipseudomonal beta-lactams.

100 A to analyze the gene expression response to ertapenem or meropenem treatment and found significant e

101 g sensitivities of Trypticase soy broth plus ertapenem or meropenem were 78% and 47%, respectively.

102 mined the utility of adjunctive carbapenems (ertapenem or meropenem) to enhance the efficacy of cefta

103 evaluations of diversified groups of over 57 ertapenem prodrugs which include alkyl, methylenedioxy,

104 The combination of cefazolin and ertapenem provides potent in vivo activity against MSSA

105 screening and personalized prophylaxis with ertapenem reduces SSI risk among carriers.

106 positive predictive value and specificity of ertapenem resistance for KPC detection in 2,696 Enteroba

107 positive predictive value and specificity of ertapenem resistance for KPC detection were 74% and 99.2

108 The bla(NDM-1) gene was not identified in ertapenem resistant isolates.

109 ratory sites (with 60 clinical isolates, 45% ertapenem resistant).

110 Ertapenem-resistant isolates were referred to Public Hea

111 Ertapenem-resistant isolates were referred to Public Hea

112 ents, 444 and 440 treated with sulopenem and ertapenem, respectively, had a positive baseline urine c

113 ipenem and 0.18 microM and 0.017 min(-1) for ertapenem, respectively.

114 The 1.3 A diffraction data from a 10 min ertapenem-soaked crystal revealed an isomerization occur

115 pt-2-en e-2-carboxylic acid monosodium salt (ertapenem sodium, 1), has been developed.

116 Compared to ertapenem susceptibility by Etest interpreted by CLSI M1

117 ,485 ertapenem-nonsusceptible isolates and 8 ertapenem-susceptible ESBL-positive isolates) and accoun

118 iella oxytoca, and Proteus mirabilis with an ertapenem-susceptible extended-spectrum-beta-lactamase (

119 Patients were treated with 1 g of ertapenem that was self-administered at home through a p

120 When combined with nonsusceptibility to ertapenem, the method was easy to perform and reliably d

121 romide and in 25.6% of patients who received ertapenem; the most common adverse events were mild diar

122 tatistical noninferiority of eravacycline to ertapenem to be declared for this study.

123 t is sensitive to meropenem but resistant to ertapenem to explore transcriptomic contributions to res

124 faction; further, 69 (90.8%) would recommend ertapenem to other patients.

125 , conducted from 2001 to 2004, that compared ertapenem to piperacillin-tazobactam for the treatment o

126 asymptomatic bacteriuria in the subgroup of ertapenem-treated patients who stepped down to ciproflox

127 dings, the authors conclude that a three-day Ertapenem treatment regimen is the most effective antibi

128 ed at baseline, the midcourse of intravenous ertapenem treatment, at the end of the course, and postt

129 aim was to assess the efficacy and safety of ertapenem versus piperacillin/tazobactam for foot infect

130 Ertapenem was a more sensitive indicator of KPC resistan

131 Ertapenem was generally well tolerated and had a similar

132 When meropenem or ertapenem was reacted with SHV-1 in solution, the Raman

133 robromide and 93.6% of patients who received ertapenem (weighted difference, -0.6 percentage point; 9

134 ith 258 of 419 patients (61.6%) who received ertapenem (weighted difference, -3.3 percentage points;

135 iological outcomes for patients treated with ertapenem were equivalent to those for patients treated

136 latory biologic therapies initiated prior to ertapenem were maintained throughout the treatment cours

137 e in vitro characterization of doripenem and ertapenem with BlaC.

138 penemases, by using imipenem, meropenem, and ertapenem with LC-MS/MS assays.

139 ducted to compare the safety and efficacy of ertapenem with piperacillin/tazobactam as therapy follow